Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 29%
Hold 59%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems is currently facing uncertainty surrounding reimbursement and coding of its product due to AHA recommendations, which could possibly limit growth potential in the near term. However, long-term growth potential remains positive with the introduction of a new product cycle and underpenetrated TAM. Downside risks include potential competition and changes in reimbursement, while a guidance cut on the 1Q earnings call has caused uncertainty. This analyst has therefore downgraded INSP to a neutral rating until there is more clarity on these issues.

Bears say

Inspire Medical Systems is facing significant challenges with inventory dynamics, reimbursement changes, and competition from GLP-1 drugs, which have led to a decrease in revenue growth and a significant cut in 2026 revenue guidance. This negative outlook is supported by the company's recent PT adjustment to $50, based on lower revenue estimates and a lower multiple, as well as potential future challenges that may hinder growth and profitability. Overall, there are uncertainties surrounding Inspire's near-term growth and profitability, making the stock a risky investment at this time.

INSP has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 29% recommend Buy, 59% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Hold based on their latest research and market trends.

According to 17 analysts, INSP has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.